E-celeris Competitors

ReSearch Pharmaceutical Services (RPS) merged with PRA in 2013. PRA understands that you want practical solutions that will efficiently and expertly improve your infrastructure to support business needs. Our Strategic Solutions offering provides a broad spectrum of solutions to meet sponsors where they are with their outsourcing needs. As the pioneer of the Embedded SolutionsTM model, we have mastered the art of elegant transformation as sponsors re-align their operating model to more efficiently manage their development portfolio with greater flexibility and control . Our custom-built development solutions empower companies with limited infrastructure to leverage our extensive experience to bring innovative new approaches that enhance quality, streamline development processes and improve efficiency. Our staff augmentation solutions enable sponsors to fill gaps and maintain business continuity seamlessly. For those sponsors desiring an FSP model, we bring years of experience in this method.

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,300 people across 46 countries.

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com